Increased vulnerability to L-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice

Journal of Molecular Neuroscience

Volumn 27, Issue 3, 2005, Pages 277-280

  Kariya, Shingo ^a   Takahashi, Nobuyuki ^b   Hirano, Makito ^a   Ueno, Satoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Nara City Hospital   (Japan)

Author keywords

Dopamine; Dopaminergic neuron; Neurotoxicity; Parkinson's disease; VMAT2

Indexed keywords

LEVODOPA; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; HETEROZYGOSITY; KNOCKOUT MOUSE; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; WILD TYPE;

ANIMALIA;

EID: 27644484010     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:27:3:277     Document Type: Article

References (11)

1. Brown J. M., Hanson G. R., and Fleckenstein A. E. (2001) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296, 762-767.
2. Henry J. P., Botton D., Sagne C., et al. (1994) Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 196, 251-262.
3. Jenner P. G. and Brin M. F. (1998) Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 50(Suppl. 6), S39-43.
4. Kalir H. H. and Mytilineou C. (1991) Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development. J. Neurochem. 57, 458-464.
5. Marsden C. D. (1990) Parkinson's disease. Lancet 335, 948-952.
6. O'Malley E. K., Sieber B. A., Morrison R. S., et al. (1994) Nigral type I astrocytes release a soluble factor that increases dopaminergic neuron survival through mechanisms distinct from basic fibroblast growth factor. Brain Res. 647, 83-90.
7. Reveron M. E., Savelieva K. V., Tillerson J. L., et al. (2002) L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology 23, 611-619.
8. Simuni T. and Stern M. B. (1999) Does levodopa accelerate Parkinson's disease. Drugs Aging 14, 399-408.
9. Spina M. B., Cohen G., and Marsden C. D. (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 86, 1398-1400.
10. Takahashi N., Miner L. L., Sora I., et al. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U. S. A. 94, 9938-9943.
11. Truong J. G., Rau K. S., Hanson G. R., et al. (2003) Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. Eur. J. Pharmacol. 474, 223-226.